01:58 PM EDT, 07/25/2024 (MT Newswires) -- AC Immune ( ACIU ) shares surged more than 12% in recent trading after the company said Thursday that its active-immunotherapy candidate ACI-35.030 has received fast track designation from the US Food and Drug Administration for Alzheimer's disease.

The company said ACI-35.030, now called JNJ-2056, is being developed with Johnson & Johnson's ( JNJ ) Janssen Pharmaceuticals unit.

Janssen is funding and conducting the recently initiated phase 2b clinical trial, which is currently recruiting participants with preclinical Alzheimer's disease who have yet to show clinical symptoms, AC Immune ( ACIU ) said.

Price: 3.96, Change: +0.43, Percent Change: +12.18